Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (Nasdaq: GERN).
On March 12, 2014, Geron announced that the Company has received verbal notice from the U.S. Food and Drug Administration (“FDA”) that its investigational new drug application for its only experimental drug, imetelstat for blood disorders, has been placed on full clinical hold, affecting its mid-stage trials of imetelstat because of low-grade liver function test abnormalities. The FDA expressed concern about whether these LFT abnormalities are reversible.
On this news, Geron was downgraded by MLV & Co, and the price of its shares plummeted by over 61%.
KSF’s investigation is focusing on whether Geron and/or its officers and directors violated state or federal securities laws.
If you have information that would assist KSF in its investigation, or would like to discuss your legal rights, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis Kahn (
) or KSF Partner Melinda Nicholson (
) toll free at 1-877-515-1850.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities class action and shareholder derivative litigation with offices in New York and Louisiana. KSF's lawyers have significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders.
To learn more about KSF, you may visit